Published in Int J Mol Sci on September 18, 2014
High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clin Epigenetics (2015) 0.83
Epigenetics Reactivation of Nrf2 in Prostate TRAMP C1 Cells by Curcumin Analogue FN1. Chem Res Toxicol (2016) 0.82
DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS One (2015) 0.79
Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy. Med Sci Monit (2015) 0.79
Methylation of a panel of genes in peripheral blood leukocytes is associated with colorectal cancer. Sci Rep (2016) 0.78
Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients. Med Sci Monit (2016) 0.78
Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. Oncotarget (2015) 0.78
APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.77
Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer. Epigenetics (2016) 0.77
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clin Epigenetics (2016) 0.77
DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells. PLoS One (2016) 0.77
Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis. Dis Markers (2015) 0.76
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol (2017) 0.75
CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics (2016) 0.75
Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Sci Rep (2017) 0.75
RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Oncotarget (2016) 0.75
LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality. Epigenetics (2016) 0.75
The relative contribution of DNA methylation and genetic variants on protein biomarkers for human diseases. PLoS Genet (2017) 0.75
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. Int J Mol Sci (2017) 0.75
Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. Oncol Lett (2017) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell (1992) 27.80
Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature (2011) 8.75
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med (2006) 8.25
Super-enhancers in the control of cell identity and disease. Cell (2013) 7.50
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Charting a dynamic DNA methylation landscape of the human genome. Nature (2013) 5.80
Epigenetics: regulation through repression. Science (1999) 4.57
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet (1999) 3.39
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Epidemiology of prostate cancer. Urology (2003) 2.91
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res (2007) 2.88
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat Genet (2013) 2.41
Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci (2007) 2.41
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Methylation profiling in acute myeloid leukemia. Blood (2001) 2.22
Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet (2013) 2.16
Creatinine: a review. Clin Chem (1980) 2.16
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A (2013) 2.05
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res (2007) 2.02
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
The role of RASSF1A methylation in cancer. Dis Markers (2007) 1.73
DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol (2013) 1.71
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol (2012) 1.60
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58
Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol (2009) 1.58
Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers (2011) 1.56
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res (2005) 1.46
Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res (2000) 1.40
Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci (2007) 1.37
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol (2011) 1.36
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30
DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol (2013) 1.30
Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One (2009) 1.28
Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep (2014) 1.27
The epigenetic promise for prostate cancer diagnosis. Prostate (2011) 1.26
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer (2011) 1.25
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer (2008) 1.24
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov (2012) 1.21
Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int (2011) 1.19
The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol (2007) 1.19
Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol (2012) 1.19
CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate (2008) 1.16
Biomarkers in prostate cancer: what's new? Curr Opin Oncol (2014) 1.16
Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One (2012) 1.15
Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem (2014) 1.08
Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol (2007) 1.08
Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res (2014) 1.08
Cyclooxygenase-2 in oncogenesis. Clin Chim Acta (2010) 1.08
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol (2010) 1.07
Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol (2006) 1.07
Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer (2011) 1.07
Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett (2012) 1.07
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate (2010) 1.06
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene (2012) 1.06
Methylated genes as potential biomarkers in prostate cancer. BJU Int (2010) 1.02
DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest (2010) 1.01
DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate (2009) 1.01
DNA methylation changes in prostate cancer. Methods Mol Biol (2012) 1.00
Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate (2008) 0.98
Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res (2012) 0.98
Effect of DNA methylation on identification of aggressive prostate cancer. Urology (2008) 0.98
Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer (2008) 0.98
Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci (2014) 0.96
Epigenomic alterations in localized and advanced prostate cancer. Neoplasia (2013) 0.96
CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics (2006) 0.96
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn (2012) 0.96
DNA methylation as a clinical marker in oncology. J Clin Oncol (2012) 0.94
At the tipping point for epigenetic therapies in cancer. J Clin Invest (2014) 0.94
Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol (2013) 0.93
Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int J Cancer (2010) 0.92
APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur J Hum Genet (2013) 0.92
Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther (2013) 0.92
Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis (2012) 0.91
Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One (2013) 0.90
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics (2012) 0.88